公开(公告)号：US20180236066A1

公开(公告)日：2018-08-23

申请号：US15866325

申请日：2018-01-09

Applicant: Genentech, Inc.

Inventor： Heather MAECKER ,  Bryan IRVING

IPC: A61K39/395 ,  C07K16/22 ,  C07K16/28 ,  A61K31/519 ,  A61K31/513 ,  A61K31/282 ,  A61K39/00

Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist, chemotherapy and optionally a VEGF antagonist and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.

公开(公告)号：US20180021431A1

公开(公告)日：2018-01-25

申请号：US15635920

申请日：2017-06-28

Applicant: Genentech, Inc.

Inventor： Heather MAECKER ,  Bryan IRVING

IPC: A61K39/395 ,  C07K16/28 ,  A61K31/4523 ,  A61K31/44 ,  A61K31/4355 ,  A61K31/4184 ,  C07K16/30 ,  A61K31/519 ,  A61K39/00

Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.

公开(公告)号：US20170008971A1

公开(公告)日：2017-01-12

申请号：US15184966

申请日：2016-06-16

Applicant: Genentech, Inc.

Inventor： Mark S. DENNIS ,  Allen EBENS ,  Bryan IRVING ,  Teemu T. JUNTTILA ,  Ji LI

IPC: C07K16/32 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28 ,  C07K16/30

CPC classification number: C07K16/32 ,  A61K31/282 ,  A61K31/337 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/643 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  A61K2300/00

Abstract: The invention provides compositions and methods for treating HER2-postitive cancers. The method comprising administering a PD-1 axis binding antagonist and an antibody that targets HER2.

Abstract translation: 本发明提供用于治疗HER2-肿瘤的组合物和方法。 该方法包括施用PD-1轴结合拮抗剂和靶向HER2的抗体。

公开(公告)号：US20150322153A1

公开(公告)日：2015-11-12

申请号：US14538072

申请日：2014-11-11

Applicant: GENENTECH, INC.

Inventor： Bryan IRVING ,  Henry CHIU ,  Heather MAECKER ,  Sanjeev MARIATHASAN ,  Sophie M. LEHAR ,  Yan WU ,  Jeanne CHEUNG

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30 ,  A61K45/06 ,  A61K31/7068

CPC classification number: C07K16/2827 ,  A61K31/7068 ,  A61K39/00 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/1063 ,  C07K16/22 ,  C07K16/28 ,  C07K16/30 ,  C07K16/3046 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/423 ,  Y02A50/489 ,  Y02A50/492 ,  A61K2300/00

Abstract: The present application relates to anti-PD-L1 antibodies, which have therapeutic use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.

Abstract translation: 本申请涉及抗PD-L1抗体，其具有用于增强T细胞功能以上调细胞介导的免疫应答和用于治疗T细胞功能障碍性疾病（包括感染（例如急性和慢性））和肿瘤的治疗用途 免疫。